JP2012504959A - 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 - Google Patents

複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 Download PDF

Info

Publication number
JP2012504959A
JP2012504959A JP2011531018A JP2011531018A JP2012504959A JP 2012504959 A JP2012504959 A JP 2012504959A JP 2011531018 A JP2011531018 A JP 2011531018A JP 2011531018 A JP2011531018 A JP 2011531018A JP 2012504959 A JP2012504959 A JP 2012504959A
Authority
JP
Japan
Prior art keywords
transcription factor
protein
ligand
immune
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011531018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012504959A5 (enExample
Inventor
ロバート パターソン ビーチ
トーマス ディー． リード
Original Assignee
イントレキソン コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イントレキソン コーポレーション filed Critical イントレキソン コーポレーション
Publication of JP2012504959A publication Critical patent/JP2012504959A/ja
Publication of JP2012504959A5 publication Critical patent/JP2012504959A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4234—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
JP2011531018A 2008-10-08 2009-10-08 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 Withdrawn JP2012504959A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10381008P 2008-10-08 2008-10-08
US61/103,810 2008-10-08
PCT/US2009/005510 WO2010042189A2 (en) 2008-10-08 2009-10-08 Engineered cells expressing multiple immunomodulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015157352A Division JP2016025858A (ja) 2008-10-08 2015-08-07 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用

Publications (2)

Publication Number Publication Date
JP2012504959A true JP2012504959A (ja) 2012-03-01
JP2012504959A5 JP2012504959A5 (enExample) 2012-11-29

Family

ID=42101134

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011531018A Withdrawn JP2012504959A (ja) 2008-10-08 2009-10-08 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用
JP2015157352A Withdrawn JP2016025858A (ja) 2008-10-08 2015-08-07 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用
JP2018166324A Withdrawn JP2019000118A (ja) 2008-10-08 2018-09-05 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015157352A Withdrawn JP2016025858A (ja) 2008-10-08 2015-08-07 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用
JP2018166324A Withdrawn JP2019000118A (ja) 2008-10-08 2018-09-05 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用

Country Status (12)

Country Link
US (4) US9492482B2 (enExample)
EP (1) EP2356219A4 (enExample)
JP (3) JP2012504959A (enExample)
KR (2) KR101361416B1 (enExample)
CN (1) CN102575227A (enExample)
AU (3) AU2009302804B2 (enExample)
BR (1) BRPI0920679A2 (enExample)
CA (1) CA2739902A1 (enExample)
IL (3) IL212184A (enExample)
MX (1) MX340972B (enExample)
RU (1) RU2573912C2 (enExample)
WO (1) WO2010042189A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016540505A (ja) * 2013-11-22 2016-12-28 ディーエヌエートリックス インコーポレイテッド アデノウイルス発現免疫細胞刺激受容体アゴニスト
JP2018537989A (ja) * 2015-12-18 2018-12-27 オンコセック メディカル インコーポレイテッド 異種タンパク質発現のためのプラスミド構築物及びその使用方法
JP2020011966A (ja) * 2013-04-18 2020-01-23 ティーアイエルティー・バイオセラピューティクス・オーワイＴＩＬＴ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 増強された養子細胞療法
JP2024096903A (ja) * 2016-03-17 2024-07-17 国立大学法人山口大学 免疫機能制御因子をコードする核酸、及びがん抗原を特異的に認識する細胞表面分子、ｉｌ－７及びｃｃｌ１９を発現する免疫担当細胞の作製方法
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
EP2550359B1 (en) * 2010-03-23 2017-08-09 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
EP2681327B1 (en) * 2011-03-04 2018-11-21 Intrexon Corporation Vectors conditionally expressing protein
MX369690B (es) 2011-09-08 2019-11-19 Intrexon Corp Diacilhidrazina cristalina y sus usos.
EP3692794A1 (en) * 2011-09-16 2020-08-12 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
PL3351261T3 (pl) * 2011-10-11 2021-12-06 Universität Zürich Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
CN102631671B (zh) * 2012-04-05 2014-11-26 倪国颖 提高疫苗诱导的细胞毒性t细胞反应的治疗性疫苗
BR112015026019A2 (pt) * 2013-04-11 2017-07-25 Brigham & Womens Hospital Inc métodos e composições de tratamento de doenças autoimunes
RS63601B1 (sr) * 2014-10-09 2022-10-31 Univ Yamaguchi Vektor ekspresije car i t ćelije koje eksprimiraju car
MA41538A (fr) * 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
ES2884948T3 (es) * 2014-12-03 2021-12-13 Azusapharma Sciences Inc Plásmido de coexpresión
ES2841353T3 (es) 2014-12-09 2021-07-08 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado
CA2974903A1 (en) * 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
US10808230B2 (en) * 2015-02-24 2020-10-20 Board Of Regents, The University Of Texas System Selection methods for genetically-modified T cells
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
US20170020922A1 (en) * 2015-07-16 2017-01-26 Batu Biologics Inc. Gene editing for immunological destruction of neoplasia
AU2016334401A1 (en) 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
WO2017083750A1 (en) 2015-11-11 2017-05-18 Intrexon Corporation Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
EP3400291B2 (en) 2016-01-08 2024-02-28 Replimune Limited Engineered virus
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN118652336A (zh) 2016-06-08 2024-09-17 普瑞赛格恩公司 Cd33特异性嵌合抗原受体
US12281339B2 (en) * 2016-07-05 2025-04-22 Polaris Group Combination cancer immunotherapies with arginine depletion agents
UY37343A (es) 2016-07-25 2018-02-28 Intrexon Corp Control del fenotipo en plantas
JP2018023343A (ja) * 2016-08-12 2018-02-15 国立大学法人山口大学 細胞培養用培地、及び細胞培養方法
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CA3049652A1 (en) 2017-01-10 2018-07-19 Intrexon Corporation Modulating expression of polypeptides via new gene switch expression systems
EP3591041B1 (en) * 2017-02-28 2025-04-30 Genemedicine Co., Ltd. ANTICANCER COMPOSITION COMPRISING A TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND AN IMMUNE CHECKPOINT INHIBITOR
KR20190141695A (ko) 2017-04-13 2019-12-24 센티 바이오사이언시스, 인코포레이티드 병용 암 면역요법
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
EP3635132A4 (en) 2017-06-07 2021-05-26 Intrexon Corporation EXPRESSION OF NOVEL CELL MARKERS
US20200123566A1 (en) * 2017-06-13 2020-04-23 Oncosec Medical Incorporated Multigene construct for immune-modulatory protein expression and methods of use
JP7102670B2 (ja) * 2018-01-25 2022-07-20 アイ－エムエービー バイオファーマ ユーエス リミテッド 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
WO2019151760A1 (ko) * 2018-02-02 2019-08-08 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
JP2021512950A (ja) * 2018-02-02 2021-05-20 エスエル・ベクシジェン・インコーポレイテッドＳｌ Ｖａｘｉｇｅｎ， Ｉｎｃ． 新規なワクチンの免疫補助剤
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
IL277128B2 (en) 2018-03-06 2025-11-01 Precigen Inc Hepatitis b vaccines and uses of the same
SG11202008539YA (en) 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same
JP2021523743A (ja) 2018-05-15 2021-09-09 カースゲン セラピューティクス カンパニー リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｃｏ．， Ｌｔｄ． 遺伝子操作された細胞及びその応用
EP3807423A4 (en) * 2018-06-13 2022-04-27 The Council Of The Queensland Institute Of Medical Research Viral detection assay
CN112601547A (zh) 2018-06-21 2021-04-02 雷普利穆内有限公司 使用溶瘤病毒的治疗
SG11202012203PA (en) * 2018-06-27 2021-01-28 Precigen Inc In vivo controlled combination therapy for treatment of cancer
US12473533B2 (en) 2018-07-09 2025-11-18 The Regents Of The University Of California Gene targets for T-cell-based immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CA3116138A1 (en) 2018-10-17 2020-04-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
TWI850282B (zh) 2018-11-27 2024-08-01 香港商弘年發展有限公司 用於治療癌症之質體建構體和使用方法
SG11202105422RA (en) * 2018-11-29 2021-06-29 Virogin Biotech Canada Ltd Hsv vector with reduced neurotoxicity
WO2020131656A1 (en) * 2018-12-17 2020-06-25 Immune Design Corp. Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancer
WO2020206056A1 (en) 2019-04-04 2020-10-08 Greenvenus Llc Peptides and methods of plant protection
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
US20220280609A1 (en) * 2019-07-17 2022-09-08 The Regents Of The University Of California Combination cancer therapy agents and methods
CN110354260B (zh) * 2019-08-19 2020-06-26 启辰生生物科技(珠海)有限公司 免疫增强剂、药物组合物及其应用
CN110732021B (zh) * 2019-11-21 2020-08-25 北京启辰生生物科技有限公司 用于解除肿瘤免疫抑制的组合物及其应用
EP4061485A4 (en) * 2019-11-22 2023-12-20 Alaunos Therapeutics, Inc. METHOD FOR TREATING GLIOBLASTOMA
CN110904050B (zh) * 2019-12-16 2021-02-05 启辰生生物科技(珠海)有限公司 工程化抗原递呈细胞、免疫调节组合物及应用
CN113005090A (zh) * 2019-12-20 2021-06-22 上海细胞治疗集团有限公司 共表达趋化因子和共刺激分子的dc细胞及其应用
WO2021163874A1 (zh) * 2020-02-18 2021-08-26 苏州工业园区唯可达生物科技有限公司 一种重组病毒载体、包含其的免疫组合物以及用途
AU2021236879A1 (en) * 2020-03-16 2022-11-10 Vrije Universiteit Brussel A mixture of mRNA to enhance the potency of dendritic cells
CN112029730A (zh) * 2020-05-20 2020-12-04 深圳市芥至和生物科技有限公司 一种基因修饰的间充质干细胞及其应用
WO2021251707A1 (ko) * 2020-06-09 2021-12-16 사회복지법인 삼성생명공익재단 Nk 세포의 활성화 및 증폭을 위해 유전적으로 조작된 세포주, 및 그의 용도
JP2023548746A (ja) 2020-10-13 2023-11-21 クリヤ セラピューティクス インコーポレイテッド サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
CN116426483B (zh) * 2021-12-30 2024-02-23 南京紫珑生物科技有限公司 Cd258蛋白在免疫治疗中的应用
CN114426585B (zh) * 2022-02-15 2023-10-03 广东香雪干细胞再生医学科技有限公司 融合蛋白及其表达细胞株与应用
CN115433734B (zh) * 2022-06-01 2025-03-04 北京奇糖科技有限公司 核酸片段及其在制备肿瘤疫苗中的应用
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
CN119470910A (zh) * 2024-11-01 2025-02-18 安徽医科大学 一种IL-12p70蛋白在认知障碍疾病中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524595A (ja) * 2003-02-28 2007-08-30 レオジーン， インコーポレイテッド エクジソン受容体複合体を通して外因性遺伝子の発現を調節するための生物学的利用能のあるジアシルヒドラジン・リガンド

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018925A2 (en) 1996-10-29 1998-05-07 Valentis, Inc. Modified glucocorticoid receptors, glucocorticoid receptors/progesterone receptors hybrids
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
WO1994017208A1 (en) 1993-01-21 1994-08-04 President And Fellows Of Harvard College Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound
US5698413A (en) 1993-05-05 1997-12-16 The United States Of America As Represented By The Department Of Health And Human Services Method of evaluating chemotherapeutic agents in vivo
US20040265288A1 (en) * 1995-03-08 2004-12-30 Gilman Michael Z. New applications of gene therapy technology
US5744304A (en) 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
US6306649B1 (en) 1995-06-27 2001-10-23 Ariad Gene Therapeutics, Inc. Heterologous transcription factors
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
US20040086494A1 (en) 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US20040103448A1 (en) 1997-09-05 2004-05-27 Anders Bjorklund Methods for inducing in vivo proliferation and migration of transplanted progenitor cells in the brain
JP2001523480A (ja) 1997-11-20 2001-11-27 バイカル インコーポレイテッド サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6866842B1 (en) 1998-05-01 2005-03-15 University Of Pittsburgh Muscle-derived cells (MDCs) for treating muscle-or bone-related injury or dysfunction
US7279565B2 (en) 1998-05-05 2007-10-09 Richard Voellmy Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress
JP4768916B2 (ja) 1998-09-15 2011-09-07 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション サイトカイン発現が遺伝的に増強された抗原提示細胞のインサイチュ注入
WO2000031286A1 (en) * 1998-11-20 2000-06-02 Valentis, Inc. Adenoviral vector-mediated delivery of modified steroid hormone receptors and related products and methods
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6696272B1 (en) 1999-06-02 2004-02-24 Hsc Research & Development Limited Partnership Products and methods for gaucher disease therapy
WO2001070816A2 (en) 2000-03-22 2001-09-27 Rohm And Haas Company Ecdysone receptor-based inducible gene expression system
AU2001296354A1 (en) * 2000-09-25 2002-04-02 Baylor College Of Medicine Improved system for regulation of transgene expression
US20030180719A1 (en) 2001-04-13 2003-09-25 Thomas Herget Human cellular protein gastrointestinal glutathione peroxidase as target for medical intervention against hepatitis C virus infections
AU2002307393A1 (en) 2001-04-20 2002-11-05 The Salk Institute For Biological Studies Inducible expression of transfected genes
US20030221203A1 (en) * 2001-10-03 2003-11-27 Agha-Mohammadi Siamak High efficiency regulatable gene expression system
DE60234115D1 (de) * 2001-11-29 2009-12-03 Dandrit Biotech As Pharmazeutische zusammensetzung zur auslösung einer immunantwort bei einem menschen oder einem tier
GB0216286D0 (en) 2002-07-15 2002-08-21 Univ Leeds Network
WO2004035787A2 (de) * 2002-10-14 2004-04-29 F. Hoffmann-La Roche Ag Transplantierbare zelle mit immunmodulator
CA2516320C (en) * 2003-02-18 2015-05-26 Kevin Slawin Induced activation in dendritic cells
US7304162B2 (en) * 2003-02-21 2007-12-04 Intrexon Corporation Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
CA2517245C (en) 2003-02-28 2009-01-20 Mcgill University Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
CA2519680A1 (en) * 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
ES2375565T3 (es) 2003-08-07 2012-03-02 Healor Ltd. Composiciones farmacéuticas y métodos para acelerar la cicatrización de heridas.
WO2005033297A1 (en) 2003-09-19 2005-04-14 The Rockefeller University Compositions, methods and kits relating to reprogramming adult differentiated cells and production of embryonic stem cell-like cells
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
WO2005099773A1 (en) 2004-04-05 2005-10-27 University Of Vermont And State Agricultural College Use of erythropoietin for treatment of cancer
US7704714B2 (en) 2004-07-26 2010-04-27 Agency For Science, Technology & Research Encapsulation of cells in biologic compatible scaffolds by coacervation of charged polymers
US20060067942A1 (en) 2004-09-24 2006-03-30 Salama Zoser B Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals
UY29544A1 (es) 2005-05-19 2006-12-29 Schering Ag Tratamiento de enfermedades usando un sistema mejorado de expresión regulada
CN101501055B (zh) 2005-06-23 2016-05-11 贝勒医学院 负性免疫调节因子的调节和免疫疗法应用
US20070036770A1 (en) 2005-08-12 2007-02-15 Wagner Darrell O Biologic device for regulation of gene expression and method therefor
CA2626056A1 (en) 2005-11-18 2007-05-24 Ares Trading S.A. Interferon in influenza
EP1971288B1 (en) 2005-12-30 2013-02-13 Neurotech USA, Inc. Micronized device for the delivery of biologically active molecules and methods of use thereof
US20080181874A1 (en) * 2007-01-29 2008-07-31 Alexander Kharazi Cell composition and method for treating cancer
US20080241100A1 (en) 2007-03-27 2008-10-02 Stefan Strobl Pharmaceutical composition comprising a cytokine
MX363066B (es) 2007-05-29 2019-03-07 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
US20090017108A1 (en) 2007-07-11 2009-01-15 Alexander Yuzhakov Liposome compositions for treatment of hepatitis C
US20090098055A1 (en) 2007-08-23 2009-04-16 Intrexon Corporation Methods and Compositions for Diagnosing Disease
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
JP2010539993A (ja) * 2007-10-08 2010-12-24 イントレキソン コーポレーション 遺伝子操作した樹状細胞および癌の治療のための使用
EP2550359B1 (en) 2010-03-23 2017-08-09 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524595A (ja) * 2003-02-28 2007-08-30 レオジーン， インコーポレイテッド エクジソン受容体複合体を通して外因性遺伝子の発現を調節するための生物学的利用能のあるジアシルヒドラジン・リガンド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014017010; Ｔｒｅｎｄｓ　Ｉｍｍｕｎｏｌ． ２２　（３）, 2001, ｐ．１１３-１１５ *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020011966A (ja) * 2013-04-18 2020-01-23 ティーアイエルティー・バイオセラピューティクス・オーワイＴＩＬＴ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ Ｏｙ 増強された養子細胞療法
JP7114532B2 (ja) 2013-04-18 2022-08-08 ティーアイエルティー・バイオセラピューティクス・オーワイ 増強された養子細胞療法
US12421502B2 (en) 2013-04-18 2025-09-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
JP2016540505A (ja) * 2013-11-22 2016-12-28 ディーエヌエートリックス インコーポレイテッド アデノウイルス発現免疫細胞刺激受容体アゴニスト
JP2020048582A (ja) * 2013-11-22 2020-04-02 ディーエヌエートリックス インコーポレイテッド アデノウイルス発現免疫細胞刺激受容体アゴニスト
JP2018537989A (ja) * 2015-12-18 2018-12-27 オンコセック メディカル インコーポレイテッド 異種タンパク質発現のためのプラスミド構築物及びその使用方法
JP7079729B2 (ja) 2015-12-18 2022-06-02 オンコセック メディカル インコーポレイテッド 異種タンパク質発現のためのプラスミド構築物及びその使用方法
JP2022116129A (ja) * 2015-12-18 2022-08-09 オンコセック メディカル インコーポレイテッド 異種タンパク質発現のためのプラスミド構築物及びその使用方法
JP2024096903A (ja) * 2016-03-17 2024-07-17 国立大学法人山口大学 免疫機能制御因子をコードする核酸、及びがん抗原を特異的に認識する細胞表面分子、ｉｌ－７及びｃｃｌ１９を発現する免疫担当細胞の作製方法

Also Published As

Publication number Publication date
IL212184A0 (en) 2011-06-30
IL253985A0 (en) 2017-10-31
KR20130116079A (ko) 2013-10-22
WO2010042189A2 (en) 2010-04-15
AU2015234302B2 (en) 2017-02-16
AU2009302804B2 (en) 2015-07-02
US9492482B2 (en) 2016-11-15
IL242254A0 (en) 2015-11-30
MX2011003762A (es) 2011-04-27
KR101361416B1 (ko) 2014-02-21
MX340972B (es) 2016-08-02
EP2356219A4 (en) 2017-07-05
US20160089398A1 (en) 2016-03-31
IL212184A (en) 2015-10-29
AU2017203273A1 (en) 2017-06-08
CN102575227A (zh) 2012-07-11
CA2739902A1 (en) 2010-04-15
JP2019000118A (ja) 2019-01-10
US20170128569A1 (en) 2017-05-11
AU2009302804A1 (en) 2010-04-15
WO2010042189A3 (en) 2016-03-24
US10046049B2 (en) 2018-08-14
KR20110065565A (ko) 2011-06-15
KR101629071B1 (ko) 2016-06-09
IL253985B (en) 2018-04-30
BRPI0920679A2 (pt) 2022-05-17
US20110268766A1 (en) 2011-11-03
RU2011113660A (ru) 2012-11-20
RU2573912C2 (ru) 2016-01-27
JP2016025858A (ja) 2016-02-12
AU2015234302A1 (en) 2015-10-29
EP2356219A2 (en) 2011-08-17
US20180333486A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
JP2019000118A (ja) 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用
JP6290270B2 (ja) 遺伝子操作した樹状細胞および癌の治療のための使用
JP6732704B2 (ja) 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
HK1146300B (en) Engineered dendritic cells and uses for the treatment of cancer

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20111005

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20111005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140513

AA92 Notification that decision to refuse application was cancelled

Free format text: JAPANESE INTERMEDIATE CODE: A971092

Effective date: 20140527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140610

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140908

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150807

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150928

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20151204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170721

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170829

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170830